A L Hanlon

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology
    A L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 46:559-66. 2000
  2. ncbi Patterns and fate of PSA bouncing following 3D-CRT
    A L Hanlon
    Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 50:845-9. 2001
  3. ncbi Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer
    Alexandra L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 58:43-52. 2004
  4. ncbi Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population
    A L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 49:51-9. 2001
  5. ncbi Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer
    Alexandra L Hanlon
    Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 53:297-303. 2002
  6. ncbi Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 89:2018-24. 2000
  7. ncbi Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 42:43-50. 1998
  8. ncbi Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer
    W H Pinover
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 47:649-54. 2000
  9. ncbi Dose selection for prostate cancer patients based on dose comparison and dose response studies
    G E Hanks
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 46:823-32. 2000
  10. ncbi Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques
    E M Horwitz
    Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, Pennsylvania 19111, USA
    Cancer 92:1281-7. 2001

Collaborators

Detail Information

Publications75

  1. ncbi Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology
    A L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 46:559-66. 2000
    ....
  2. ncbi Patterns and fate of PSA bouncing following 3D-CRT
    A L Hanlon
    Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 50:845-9. 2001
    ....
  3. ncbi Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer
    Alexandra L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 58:43-52. 2004
    ....
  4. ncbi Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population
    A L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 49:51-9. 2001
    ..whole pelvis with prostate boost. Second, bowel and bladder QOL measures for these patients were compared to those of the normal population of men with a similar age distribution...
  5. ncbi Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer
    Alexandra L Hanlon
    Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 53:297-303. 2002
    ..To link posttreatment biochemical profiles to distant failure and cause-specific survival by assessing the relationship between posttreatment prostate-specific antigen (PSA) nadir and PSA doubling time (PSADT) with these outcome measures...
  6. ncbi Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 89:2018-24. 2000
    ..The purpose of this study was to analyze the extent of hypoxia in prostate carcinoma tumors using the Eppendorf pO(2) microelectrode and correlate this with pretreatment characteristics and prognostic factors...
  7. ncbi Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 42:43-50. 1998
    ....
  8. ncbi Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer
    W H Pinover
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 47:649-54. 2000
    ....
  9. ncbi Dose selection for prostate cancer patients based on dose comparison and dose response studies
    G E Hanks
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 46:823-32. 2000
    ..To better define the appropriate dose for individual prostate cancer patients treated with three-dimensional conformal radiation therapy (3D CRT)...
  10. ncbi Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques
    E M Horwitz
    Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, Pennsylvania 19111, USA
    Cancer 92:1281-7. 2001
    ....
  11. ncbi The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer
    E M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 45:1219-25. 1999
    ..However, in this era of cost consciousness and limited resources, the cost effectiveness of 3DCRT compared with conventional external beam irradiation (CRT) remains unexamined...
  12. ncbi Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy
    P R Anderson
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 89:2565-9. 2000
    ..The purpose of this study was to determine the biochemical outcome and factors predictive of outcome in prostate carcinoma patients with Gleason score 7 tumors who were treated with three-dimensional conformal radiation therapy (3DCRT)...
  13. ncbi Is there a subset of patients with PSA > or = 20 ng/ml who do well after conformal beam radiotherapy?
    O Algan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Radiat Oncol Investig 7:106-10. 1999
    ..However, because of the small patient numbers, these results will need to be validated with longer follow up...
  14. ncbi Evidence for cure of 'young' men with prostate cancer
    G E Hanks
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 15:563-7; discussion 571-4. 2001
    ..Few failures occur after 5 years' follow-up and the percentage cured is similar to that with prostatectomy, with much less morbidity. Appropriate dose is necessary to optimize outcome...
  15. ncbi Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer
    D Cvetkovic
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Urology 57:821-5. 2001
    ..The results of our study further support the exploration of antiangiogenesis strategies for the treatment of human prostate cancer...
  16. ncbi Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer?
    E M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Radiat Oncol Investig 7:249-59. 1999
    ..Long-term observation will be necessary to see if improvements in bNED control will translate into improvements in overall survival...
  17. ncbi Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089
    T E Le Voyer
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:2912-9. 2003
    ..CONCLUSION: The number of lymph nodes analyzed for staging colon cancers is, itself, a prognostic variable on outcome. The impact of this variable is such that it may be an important variable to include in evaluating future trials...
  18. ncbi Update on the treatment of prostate cancer with external beam irradiation
    E M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 37:195-206. 1998
    ....
  19. ncbi Diabetes mellitus: a predictor for late radiation morbidity
    D M Herold
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 43:475-9. 1999
    ....
  20. ncbi Hypoxia in human prostate carcinoma: an Eppendorf PO2 study
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Am J Clin Oncol 24:458-61. 2001
    ..More patients will be accrued to this study to ultimately correlate the oxygenation status in prostate carcinoma tumors with treatment outcome...
  21. ncbi Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer
    D L Winter
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Urology 58:614-8. 2001
    ..The ability of these markers to predict earlier disease onset is currently under investigation...
  22. ncbi Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation
    G M Freedman
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 20:4015-21. 2002
    ....
  23. ncbi Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation
    A R Sasson
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Cancer 91:1862-9. 2001
    ..The risk of local recurrence appears to be modified by the use of tamoxifen. Further studies are needed to address this issue...
  24. ncbi Incidental parathyroidectomy during thyroid surgery does not cause transient symptomatic hypocalcemia
    A R Sasson
    Head and Neck Surgery Section, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    Arch Otolaryngol Head Neck Surg 127:304-8. 2001
    ..Modified radical neck dissection may increase the risk of incidental parathyroidectomy. Most of the glands removed were intrathyroidal, so changes in surgical technique are unlikely to markedly reduce this risk...
  25. ncbi Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 63:1455-62. 2005
    ..To compare several characteristics of alternative definitions of biochemical failure (BF) in men with extended follow-up after radiotherapy (RT) with or with androgen deprivation therapy (ADT) for prostate cancer...
  26. ncbi Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
    Stephen F Andrews
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 104:299-304. 2005
    ..There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes...
  27. ncbi Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 62:397-405. 2005
    ..To determine whether the use of androgen deprivation (AD) increases late morbidity when combined with high-dose three-dimensional conformal radiation therapy (3D-CRT)...
  28. ncbi Pattern of local recurrence after conservative surgery and whole-breast irradiation
    Gary M Freedman
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 61:1328-36. 2005
    ..We analyzed the long-term risk of recurrence by area of the breast after whole-breast irradiation...
  29. ncbi Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 61:1291-8. 2005
    ..The American Society of Therapeutic Radiation Oncology definition for biochemical failure overestimates BF in 20-30% after RT+AD compared to 5% after RT alone...
  30. ncbi The surgical management of superior sulcus tumors: a retrospective review with long-term follow-up
    Melvyn Goldberg
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Ann Thorac Surg 79:1174-9. 2005
    ..We reviewed our experience with multimodality therapy for superior sulcus tumors to identify aspects of treatment that impact survival...
  31. ncbi What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:1003-10. 2005
    ..The purpose of this study was to determine what pretreatment (initial) PSA (iPSA) level, if any, warrants the addition of long-term androgen deprivation in the PSA era...
  32. ncbi Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:695-701. 2005
    ..These data suggest that the primary tumor takes precedence over lymph node coverage or the use of STAD. Doses >70 Gy are of paramount importance in such intermediate- and high-risk patients...
  33. ncbi In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046
    Mark K Buyyounouski
    Int J Radiat Oncol Biol Phys 60:1664-5; author reply 1666. 2004
  34. ncbi Parity confers better prognosis in older women with early-stage breast cancer treated with breast-conserving therapy
    Penny R Anderson
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Clin Breast Cancer 5:225-31. 2004
    ..Parity can be considered a prognostic factor in elderly patients with early-stage breast cancer, and therefore may be used as a tool for identifying patients who may benefit from a more aggressive treatment approach...
  35. ncbi Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performance
    Scott G Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 70:1169-75. 2008
    ..To define and incorporate the impact of the percentage of positive biopsy cores (PPC) into a predictive model of prostate cancer radiotherapy biochemical outcome...
  36. ncbi Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 64:518-26. 2006
    ..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial...
  37. ncbi Importance of physical examination in the absence of a mammographic abnormality for the detection of early-stage breast cancer
    Hasmik Diratzouian
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Clin Breast Cancer 6:330-3. 2005
    ..Physical examination remains an important method of detection of breast cancer, particularly for younger women for whom mammography is less sensitive and not performed as frequently...
  38. ncbi Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 70:59-66. 2008
    ..The present study examined the clinical utility of the interval to biochemical failure (IBF) as a prognostic factor for distant metastasis (DM) and prostate cancer-specific mortality (PCSM) after radiotherapy...
  39. ncbi Local minocycline as an adjunct to surgical therapy in moderate to severe, chronic periodontitis
    Maj Karin Hellström
    Department of Periodontology, Institute of Odontology, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    J Clin Periodontol 35:525-31. 2008
    ..The aim of the study was to evaluate the effects of minocycline microspheres on periodontal probing depth reduction when used in combination with surgery in adults with moderate to severe, chronic periodontitis...
  40. ncbi Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 110:68-80. 2007
    ..The authors hypothesized that early failures due to subclinical micrometastasis at presentation could be differentiated from late failures due to local persistence...
  41. ncbi Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy
    Mary Feng
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 68:1417-23. 2007
    ..To determine the rate and magnitude of late genitourinary (GU) and gastrointestinal (GI) toxicities after salvage or adjuvant radiotherapy (RT) for prostate cancer, and to determine predictive factors for these toxicities...
  42. ncbi A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Thorac Oncol 2:287-92. 2007
    ..To determine the feasibility of combining concurrent carboplatin/paclitaxel and thoracic radiotherapy (TRT) for completely resected stage II and IIIA non-small cell lung cancer...
  43. ncbi What dose of external-beam radiation is high enough for prostate cancer?
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:682-9. 2007
    ..To quantify the radiotherapy dose-response of prostate cancer, adjusted for prognostic factors in a mature cohort of men treated relatively uniformly at a single institution...
  44. ncbi The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer
    Alexandra L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 67:1082-7. 2007
    ..To investigate the prognostic utility of the proportion of prostate biopsy tissue containing Gleason pattern 4 or 5 (GP4/5) after definitive radiotherapy (RT) for prostate cancer...
  45. ncbi Radiation dose and late failures in prostate cancer
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 67:1074-81. 2007
    ..To quantify the impact of radiation dose escalation on the timing of biochemical failure (BF) and distant metastasis (DM) for prostate cancer treated with radiotherapy (RT) alone...
  46. ncbi A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 29:458-62. 2006
    ..The purpose of this report is to determine whether any specific magnitude in the prostate specific antigen (PSA) bounce predicted for a clinically poorer outcome...
  47. ncbi Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer
    Gary M Freedman
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Am J Clin Oncol 29:66-70. 2006
    ..Our hypothesis is that measures to decrease dose inhomogeneity within the breast and skin with IMRT will improve acute skin toxicity...
  48. ncbi The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:1383-91. 2004
    ..Intensity-modulated radiation therapy may offer further reductions in the doses received by the PB and CB; however, at what cost to prostate coverage and normal tissue sparing will be the subject of a follow-up study...
  49. ncbi Low complication rates are achievable after postmastectomy breast reconstruction and radiation therapy
    Penny R Anderson
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:1080-7. 2004
    ..To report our institution's experience of complications and cosmetic results among patients who underwent modified radical mastectomy followed by reconstruction and radiation therapy (RT)...
  50. ncbi Matched-cohort analysis of patients with prostate cancer followed with observation or treated with three-dimensional conformal radiation therapy
    Noel M Kramer
    Departments of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    BJU Int 94:59-62. 2004
    ..As the follow-up was short a longer follow-up is needed to determine whether the outcome of those patients who chose observation will remain comparable to that in those undergoing immediate 3-DCRT...
  51. ncbi Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Urol 169:2153-7; discussion 2157-9. 2003
    ..Additional analysis with large numbers of patients from multiple institutions is necessary to determine the point...
  52. ncbi Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:337-49, x. 2003
    ..In summary, advances in radiation oncology have led to significant gains in prostate cancer control. Clinical prognostic factor-based patient selection is central to the optimization of outcome...
  53. ncbi Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection
    Natalie E Joseph
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Ann Surg Oncol 10:213-8. 2003
    ..Most patients are understaged. Underestimating nodal stage may influence decisions regarding adjuvant therapy, as well as overall prognosis...
  54. ncbi Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Radiother Oncol 66:173-9. 2003
    ..Our data confirms the validity of the RTOG 98-05 implant guidelines for pre-implant planning as it relates to enlargement of the CTV to ensure adequate margin between the CTV and the prescription isodose lines...
  55. ncbi Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy
    Wayne H Pinover
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 97:1127-33. 2003
    ....
  56. ncbi Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement
    Derek B Chism
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 55:71-7. 2003
    ..A dose of 79-84 Gy can be safely delivered to the prostate, with a 9% rate of late Grade 2 GI, 12% rate of late Grade 2 GU, and 2% rate of late Grade 3 GU complications...
  57. ncbi Tumor above the spinal accessory nerve in papillary thyroid cancer that involves lateral neck nodes: a common occurrence
    James F Pingpank
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Arch Otolaryngol Head Neck Surg 128:1275-8. 2002
    ..quot;Skip" metastases and cancer above the spinal accessory nerve are common. Neck dissections should include all node stations likely to be involved because selective node excision is likely to leave metastatic disease in situ...
  58. ncbi Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 60:634-9. 2002
    ..The P/M PO2 ratio was the strongest predictor for biochemical control on stepwise multivariate analysis. Longer follow up with more patients is planned to confirm this result...
  59. ncbi Dose response in prostate cancer with 8-12 years' follow-up
    Gerald E Hanks
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 54:427-35. 2002
    ..The dose response in prostate cancer is real, and the absence of biochemical recurrence after 8 years demonstrates the lack of late failure and suggests cure...
  60. ncbi Biochemical failure rates in prostate cancer patients predicted to have biologically insignificant tumors treated with three-dimensional conformal radiation therapy
    Noel M Kramer
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 53:277-81. 2002
    ....
  61. ncbi Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control
    Joseph M Kaminski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 52:888-92. 2002
    ..PSA nadir did not correlate with bNED status in the favorable patients, but it was strongly predictive in the unfavorable patients. Prostate gland volume was also predictive of bNED failure in the favorable but not the unfavorable group...
  62. ncbi The Gleason score shift: score four and seven years ago
    Derek B Chism
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 56:1241-7. 2003
    ..The GS shift confounds retrospective series spanning the 1990s...
  63. ncbi Positive prostate biopsy laterality and implications for staging
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 62:298-303. 2003
    ..04). CONCLUSIONS: Inclusion of positive biopsy laterality status into clinical staging causes stage migration without reflecting a change in outcome and should not be used...
  64. ncbi Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapy
    Stephen F Andrews
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:475-80. 2004
    ..On multivariate analysis, no predictors were found for better local control; however, the numbers of Stage III and high-grade patients were small, which may have masked a possible benefit of BT plus EBRT in this population...
  65. ncbi A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy
    Derek B Chism
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111-2497, USA
    Int J Radiat Oncol Biol Phys 59:380-5. 2004
    ..CONCLUSIONS: The SF model created prognostic groups with a greater internal consistency than the DF model. The SF was also better at identifying patients with high-risk prostate cancer who may benefit from a more aggressive approach...
  66. ncbi Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 58:743-9. 2004
    ..A Phase III randomized trial has been designed to test the clinical significance of the erectile tissue-sparing technique described here...
  67. ncbi Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database
    Mark K Buyyounouski
    J Urol 171:1246-7; author reply 1247. 2004
  68. ncbi Prostate cancer radiotherapy dose response: an update of the fox chase experience
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Urol 171:1132-6. 2004
    ....
  69. ncbi The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111-2497, USA
    Cancer 100:538-43. 2004
    ..CONCLUSIONS: Escalation of RT dose reduced the rates of BF, DM, and OM significantly in patients with prostate cancer. The inclusion of YOT had a pronounced effect on these correlations that may confound interpretation...
  70. ncbi Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?
    Khanh H Nguyen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:377-83. 2003
    ....
  71. ncbi Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older
    Gary M Freedman
    Department of Radiation Oncology, the Breast Evaluation Center, Fox Chase Cancer Center, Philadelphia, PA, USA
    Cancer 98:918-25. 2003
    ..Women who underwent mammographic screening were found to have smaller tumors, which resulted in a majority of these patients being able to consider breast conservation as an alternative to mastectomy...
  72. ncbi Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth
    Joseph M L Kaminski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:24-8. 2003
    ..0024). CONCLUSION: The results suggest that neoadjuvant AD may result in prolonged suppression of tumor growth, even after testosterone replacement...
  73. ncbi Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:19-23. 2003
    ..However, little evidence is available to show that BF is associated with death for patents with prostate cancer treated with radiotherapy. We examined the relationship between BF and death from prostate cancer...
  74. ncbi Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 68:599-609. 2008
    ..In this study, we investigated the effects of AS-MDM2 combined with AD on androgen resistant LNCaP (LNCaP-Res) and moderately androgen resistant bcl-2 overexpressing LNCaP (LNCaP-BST) cells...
  75. ncbi The natural history of observed enhancing renal masses: meta-analysis and review of the world literature
    Sam N Chawla
    Department of Urologic Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19111, USA
    J Urol 175:425-31. 2006
    ..Therefore, physicians and patients assume a calculated risk when following these tumors. Basic biological data are needed to assess the natural history of untreated renal masses...